70 related articles for article (PubMed ID: 28639416)
1. Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
Joffe E; Ariela Arad N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Goldschmidt N; Polliack A; Herishanu Y
Hematol Oncol; 2018 Feb; 36(1):128-135. PubMed ID: 28639416
[TBL] [Abstract][Full Text] [Related]
2. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Herling CD; Cymbalista F; Groß-Ophoff-Müller C; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Busch R; Porcher R; Cazin B; Dreyfus B; Ibach S; Leprêtre S; Fischer K; Kaiser F; Eichhorst B; Wentner CM; Hoechstetter MA; Döhner H; Leblond V; Kneba M; Letestu R; Böttcher S; Stilgenbauer S; Hallek M; Levy V
Leukemia; 2020 Aug; 34(8):2038-2050. PubMed ID: 32071431
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Wang XV; Hanson CA; Tschumper RC; Lesnick CE; Braggio E; Paietta EM; O'Brien S; Barrientos JC; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Erba H; Stone R; Litzow MR; Tallman MS; Shanafelt TD; Kay NE
Blood; 2021 Dec; 138(26):2810-2827. PubMed ID: 34407545
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Kutsch N; Giza A; Robrecht S; Stumpf J; Federhen A; Stoltefuß A; Vehling-Kaiser U; Koenigsmann M; Tausch E; Schneider C; Stilgenbauer S; Illmer T; Schlag R; Dörfel S; Gaska T; Kiehl M; Müller-Hagen S; Moorahrend E; Linde H; Schlenska-Lange A; von Tresckow J; Fischer K; Eichhorst B; Hallek M; Fink AM
Eur J Haematol; 2024 May; ():. PubMed ID: 38693677
[TBL] [Abstract][Full Text] [Related]
5. Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia.
Rolf N; Smolen KK; Kariminia A; Velenosi A; Fidanza M; Strahlendorf C; Seif AE; Reid GSD
Cancer Immunol Immunother; 2018 Feb; 67(2):225-236. PubMed ID: 29052781
[TBL] [Abstract][Full Text] [Related]
6. Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma.
Grassberger C; Shinnick D; Yeap BY; Tracy M; G Ellsworth S; Hess CB; Weyman EA; Gallotto SL; Lawell MP; Bajaj B; Ebb DH; Ioakeim-Ioannidou M; Loeffler JS; MacDonald SM; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1044-1052. PubMed ID: 33556478
[TBL] [Abstract][Full Text] [Related]
7. The relationship between splenic dose and radiation-induced lymphopenia.
Ma Y; Kong Y; Zhang S; Peng Y; Xu M; Zhang J; Xu H; Hong Z; Xing P; Qian J; Zhang L
J Radiat Res; 2024 May; 65(3):337-349. PubMed ID: 38718391
[TBL] [Abstract][Full Text] [Related]
8. Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.
Molica S; Shanafelt TD; Allsup D; Giannarelli D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539420
[TBL] [Abstract][Full Text] [Related]
9. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.
Nørgaard CH; Jakobsen LH; Gentles AJ; Dybkær K; El-Galaly TC; Bødker JS; Schmitz A; Johansen P; Herold T; Spiekermann K; Brown JR; Klitgaard JL; Johnsen HE; Bøgsted M
PLoS One; 2018; 13(3):e0193249. PubMed ID: 29513759
[TBL] [Abstract][Full Text] [Related]
10. Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Kutsch N; Bahlo J; Robrecht S; Franklin J; Zhang C; Maurer C; De Silva N; Lange E; Weide R; Kiehl MG; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Herling M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Böttcher S; Stilgenbauer S; Fink AM; Hallek M; Eichhorst B
Hemasphere; 2020 Feb; 4(1):e336. PubMed ID: 32072150
[TBL] [Abstract][Full Text] [Related]
11. Perioperative Lymphopenia is Associated with Increased Risk of Recurrence and Worse Survival Following Hepatectomy for Hepatocellular Carcinoma.
Tsilimigras DI; Endo Y; Ratti F; Marques HP; Cauchy F; Lam V; Poultsides GA; Popescu I; Alexandrescu S; Martel G; Kitago M; Guglielmi A; Hugh T; Aldrighetti L; Gleisner A; Shen F; Endo I; Pawlik TM
Ann Surg Oncol; 2024 Apr; 31(4):2568-2578. PubMed ID: 38180707
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.
Lee G; Kim DW; Smart AC; Horick NK; Eyler CE; Roberts HJ; Pathak P; Goyal L; Franses J; Heather JM; Hwang WL; Grassberger C; Klempner SJ; Drapek LC; Allen JN; Blaszkowsky LS; Parikh AR; Ryan DP; Clark JW; Hong TS; Wo JY
Am J Clin Oncol; 2024 May; ():. PubMed ID: 38767086
[TBL] [Abstract][Full Text] [Related]
13. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.
D'Arena G; Vitale C; Perbellini O; Coscia M; La Rocca F; Ruggieri V; Visco C; Di Minno NMD; Innocenti I; Pizza V; Deaglio S; Di Minno G; Giudice A; Calapai G; Musto P; Laurenti L; Iorio EL
Eur J Haematol; 2017 Oct; 99(4):306-314. PubMed ID: 28646624
[TBL] [Abstract][Full Text] [Related]
15. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
Golay J; Ubiali G; Introna M
Haematologica; 2017 Oct; 102(10):e400-e403. PubMed ID: 28642301
[No Abstract] [Full Text] [Related]
16. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Tam C; Kuss B; Opat S; Boulos J; Marlton P
Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
18. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
19. Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?
Golay J
J Autoimmun; 2017 Dec; 85():6-19. PubMed ID: 28666691
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib may have the potential to increase radiotherapy side effects.
Gryc T; Putz F; Goerig N; Ziegler S; Fietkau R; Distel LV; Schuster B
Radiat Oncol; 2017 Jun; 12(1):109. PubMed ID: 28659152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
